BIA-ALCL And BIA-SCC
BIA_ALCL
BIA-ALCL, an acronym for breast implant-associated anaplastic large cell lymphoma, is a rare type of cancer predominantly associated with textured breast implants. Unlike conventional breast tissue cancers, BIA-ALCL develops within the fibrous scar tissue, known as the capsule, that naturally forms around the implant.
Early diagnosis and prompt intervention significantly influence the prognosis of BIA-ALCL. However, in instances where the disease progresses to metastasis, affecting regions such as the armpit lymph nodes or other anatomical sites, treatment complexities arise, diminishing the likelihood of a complete cure. Treatment modalities for advanced cases may entail procedures such as capsulectomy, implant removal, chemotherapy, radiation therapy, or stem cell transplantation. Timely medical attention is imperative upon the emergence of symptoms such as peri-implant swelling, new breast or armpit nodules, or alterations in the breast skin.
BIA-SCC
BIA-SCC, Breast Implant-Associated Squamous Cell Carcinoma, does not originate from the breast tissue itself but rather manifests as squamous cells lining the capsule surrounding the implant. While this tumor is exceedingly rare, it has the potential to metastasize to adjacent tissues such as muscles and bones, as well as distant sites including lymph nodes, lungs, and liver.
Symptoms associated with BIA-SCC often mirror those of BIA-ALCL and may include unexplained breast enlargement, pain, asymmetry, palpable lumps in the breast or armpit, skin rash overlying the breast, breast hardening, or the presence of a sizable fluid collection. Patients experiencing any of these symptoms, or others of concern should promptly seek evaluation from their healthcare provider for further assessment.
The American Society of Plastic Surgeons (ASPS) and Plastic Surgery Foundation (PSF) are currently monitoring a limited number of reported BIA-SCC cases, making it challenging to ascertain specific risk factors. The documented instances of BIA-SCC encompass patients with varying implant types—silicone and saline, both smooth and textured surfaces. Moreover, occurrences have been observed in individuals undergoing breast reconstruction following cancer and for cosmetic purposes.
BIA-SCC cases tend to manifest later in comparison to BIA-ALCL, with an average diagnosis timeframe of approximately 22 years post-initial implantation for BIA-SCC, compared to approximately 11 years for BIA-ALCL.